In a recent InvestorIntel interview, Tracy Weslosky speaks with Greg Fenton, CEO and Director of ZEN Graphene Solutions Ltd. (TSXV: ZEN) about ZEN’s exclusive worldwide rights to commercialize rapid, saliva-based COVID-19 antigen testing technology announced yesterday

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg went on to say that this saliva-based test is exceptionally accurate, similar to current PCR tests, and will “revolutionize the way testing is done”. Affordable, easy to use, scalable and provides results in under 10 minutes, Greg comments that this technology has the ability “to allow economies to reopen.” Tracy then asks the critical question with “will you be able to test for anything?”

To find out — watch the full interview, click here

About ZEN Graphene Solutions Ltd.

ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and the environment. ZEN is currently focused on commercializing ZEN Guard ^TM , a patent pending graphene-based coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar graphene compounds as pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN’s Albany Pure ^TM Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.

To learn more about ZEN Graphene Solutions Ltd., click here

Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation.  Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken,  as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [email protected].

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Jon Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF) about the application of their patented Molecular Imprint Polymers (#MIPs) technology for the detection of the COVID-19 virus, the flu and virus detection in general.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Gluckman went on to say that their patented #MIPs technology can identify molecules and may be used for detection of viruses in general and more specifically for COVID-19. He added, “We are in the phase 2 of our development for a COVID-19 test that would be completely synthetic test based on our molecular imprinted polymer technology.” Sixth Wave was recently awarded funding from the Nova Scotia COVID-19 Response Council for the development of its Accelerated Molecularly Imprinted Polymer (AMIPs™) technology for the rapid detection of viruses such as SARS-CoV-2.

Speaking on the advantages of their synthetic test Dr. Gluckman said that the two test currently used for COVID-19 detection uses biological material which is fragile and uses tremendous infrastructure to support growing of the biological materials. He explained that Sixth Wave’s technology uses synthetic polymers to detect viruses at a very low cost and allows for extended shelf life, minimal storage and handling requirements, and less sensitivity to temperature and light degradation.

To watch the complete interview, click here

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of commercial roll out of its Affinity^™ cannabinoid purification system, as well as, IXOS^®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPS^™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.

To learn more about Sixth Wave Innovations Inc., click here

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.

“You can think about our polymer almost like an antibody inside a body,” says Dr. Jonathan Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF), in an interview with InvestorIntel’s Tracy Weslosky. “A virus has a size and shape and we create an imprint in our polymer for that exact virus. Then we will detect that directly based on our chemistry,” he continued. “We are working to integrate this into masks and breathalyzers and then we can just utilize the breath, as we all know that’s the main transmission method. If you think about putting a mask on, not only will that mask provide protection, it can also, right there, be the test for COVID-19.”

Dr. Gluckman explained that Sixth Wave’s COVID-19 detection technology is currently under development but the company has successfully launched and commercialized other products with similar properties. The company has received a grant from the Canadian government to work with York University and the CTRI (Centre Technologique des Résidus Industriels) to use its virus detection technology to detect COVID-19 virus in wastewater supplies and in air handling systems.

Highlighting the advantages of Sixth Wave’s COVID-19 test over other tests, Dr. Gluckman also said that the test will be cheaper, faster and easy to use.

To access the complete interview, click here.

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.